Rayno Life Sciences-DX, Devices and Tools: CSII Revenues Up 25%

source buy fluoxetine in the uk CSII  ($12.17) stock is up 4.2% on sales growth in treatment of Peripheral Artery Disease (PAD)

Cardiovascular Systems revenues were up 25% over Fiscal Q1 2012 to $23.3M . The Q1 2013 loss was $5,2M or 26 cents a share. Shareholder equity is $28.9M with $32M in cash and $11,8M in debt. CSII was added to the Rayno Life Science Portfolio on 11/5/10 at $7.15.

Analyst sales estimates for fiscal year ending June 13 are $94.66M with an EPS loss of $1.16. The current market cap is $251M.

With the strongest market rally in a month and NASDAQ up 1.39%, many other Rayno Dx and Tools stocks rallied: http://ninacrews.com/?p=394 Abaxis (ABAX $37.56) up 2.12%, Illumina (ILMN $48.34) up 1.77%,  Sequenom (SQNM $3.23) up 3.86% and ThermoFisher (TMO $62.03) up 1.6%.

The QQQ has bounced off a recent 3 mo. low of $65.

 

 

No comments yet.

Leave a Reply